Literature DB >> 24707618

[Review of non-surgical treatment of avascular necrosis of the femoral head].

F Gómez-García.   

Abstract

Avascular necrosis of the femoral head is a frequent condition with an insidious presentation; it is initially asymptomatic and thus it is seldom diagnosed at the early stages. The purpose of this review is to update the status of the diagnosis and non-surgical treatment of avascular necrosis of the femoral head. This paper analyzes the natural history of the disease as well as the prognostic importance of early diagnosis and the identification of the extension and location of osteonecrosis. It also discusses the different nonsurgical treatment methods such as: high energy extracorporeal shock waves, electromagnetic pulsed fields, hyperbaric oxygen therapy, drugs, physical therapy, and regenerative medicine. The conclusion is that no method is effective in the advanced stages and there is great hope of treating this condition without surgery; however, progress needs to be made in research, particularly in the use of external biophysical agents and regenerative medicine. The gold standard of treatment is still surgical decompression of the femoral head at the stages in which no collapse has occurred. The prognosis apparently improves with the use of biophysical and regenerative medicine adjuvants.

Entities:  

Mesh:

Year:  2013        PMID: 24707618

Source DB:  PubMed          Journal:  Acta Ortop Mex        ISSN: 2306-4102


  2 in total

1.  Midterm results of treating femoral head osteonecrosis with autogenous corticocancellous bone grafting.

Authors:  Manouchehr Vahid Farahmandi; Mohammadreza Abbasian; Farshad Safdari; Mohammad Emami Moghaddam Tehrani
Journal:  Trauma Mon       Date:  2014-10-08

2.  Effectiveness of neuromuscular electrical stimulation and ibuprofen for pain caused by necrosis of the femoral head: A retrospective study.

Authors:  Qing-Hui Ji; Xiao-Feng Qiao; Shou-Feng Wang; Peng Zhao; Shi-Chen Liu; Yu Xue; Jian-Min Qiao; Yan-Bao Li
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.